Ind-Ra has reviewed fund-based limits worth Rs550 crore, which has been enhanced from Rs440 crore.
Company’s non-fund-based facilities reviewed are worth Rs1,135 crore.
Ind-Ra maintains a consolidated perspective of JVL and its wholly-owned subsidiaries: Jubilant Infrastructure Limited (‘IND A-‘/Stable), Jubilant Lifesciences International Pte. Ltd, Jubilant Lifesciences NV, Jubilant Lifesciences USA Inc., and Jubilant Lifesciences International Pte. Ltd., and others.
The improvement reflects consistent operating performance and deleveraging, which will result in improved credit metrics in FY22. Given its strong market position in its major products internationally, Ind-Ra has recognised JVL’s capacity to successfully pass on rising input and energy prices, despite a lag.
At around 11.38 AM, Jubilant Ingrevia was trading at Rs504, up by 0.64% against previous close of Rs500.80 on NSE. The scrip touched intraday high and low of Rs517.10 and Rs492.10 respectively, so far.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.